THE QUESTION, IN CONTEXT

Read the Barth syndrome approval alongside TAZPOWER’s limitations and the negative MMPOWER-3 trial in another mitochondrial condition.

Elamipretide, also known as SS-31, became the active substance in FORZINITY after US accelerated approval in September 2025. The indication is improvement of muscle strength in adults and children with Barth syndrome weighing at least 30 kg. A blanket statement that elamipretide is entirely unapproved is therefore outdated. Equally, the approval does not establish a general anti-ageing, energy or performance treatment for people without that rare condition.

Elamipretide interacts with cardiolipin, a component associated with the inner mitochondrial membrane. That gives researchers a biological rationale, particularly in a condition involving abnormal cardiolipin metabolism. The rationale should not be confused with an outcome across all mitochondrial disorders. Shared biological language can make several conditions sound interchangeable, but treatment evidence remains tied to the disease, participants and measurements actually investigated. Keep the molecular explanation as context while following the clinical results.

Preparing the full guide…

The extended sections are available during your one-minute preview and with free email registration.

  1. TAZPOWER’s randomised phase did not meet its primary endpoints
  2. Why the extension and accelerated approval need explanation
  3. Evidence from another mitochondrial condition was negative
  4. Keep the disease, design and endpoint together
  5. Approval does not remove the safety or product question
  6. A useful way to discuss the evidence
Full text is served after the reading access check.
FOLLOW THE EVIDENCE

Sources & further reading

Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.

  1. FDA — FORZINITY prescribing information: accelerated approval for Barth syndrome (2025)
  2. Thompson et al. — TAZPOWER: randomised trial and open-label extension in Barth syndrome (2021)
  3. FDA — FORZINITY Drug Trials Snapshot: trial design, outcomes and limitations
  4. Karaa et al. — MMPOWER-3 randomised trial in primary mitochondrial myopathy (2023)
Educational information only. Evidence for an investigational medicine, formulation or application does not establish that a supplier’s research product is equivalent. Personal treatment questions belong with a qualified clinician.
KEEP READINGPeptides explained: a clear place to beginHow peptides send signalsMedicine, supplement or research product?